AVITA Medical, Inc. RCEL
Medical/Dental Instruments · data as of November 13, 2026
AVITA Medical, Inc. (RCEL) is a healthcare company listed in the US with a market value of about $491M. In the twelve months to September 30, 2026 it had revenue of $85M and net income of -$36M, a net margin of -42.7%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 38% a year, a 5-year average ROIC of -57%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 72% below the current price.
About AVITA Medical
AVITA Medical is listed in the US and classified in medical/dental instruments. Revenue went from $692673 in 2017 to $72M in 2025, growth of about 78.6% a year. It was profitable in 0 of the last 9 years in our data. It spends 29% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 9 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85M | $72M | $64M | $50M | $34M | $29M | $14M | $5M | $929000 | $692673 |
| Net income | -$36M | -$49M | -$62M | -$35M | -$27M | -$27M | -$42M | -$25M | -$13M | -$9M |
| Free cash flow | -$20M | -$32M | -$58M | -$39M | -$20M | -$27M | -$23M | -$20M | -$13M | -$7M |
| EPS (diluted) | $-1.18 | $-1.55 | $-1.97 | $-1.13 | $-0.85 | $-0.85 | $-1.34 | $-0.80 | $-0.41 | $-0.28 |
| Net margin | -42.7% | -67.8% | -96.3% | -70.6% | -77.5% | -90.9% | -294.7% | -458.6% | -1370.8% | -1277.0% |
| ROIC | — | -114.3% | -88.6% | -36.8% | -25.4% | -17.9% | -45.0% | -107.0% | -91.0% | -224.9% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $20.70, 32% above the current price; targets range from $19.65 to $21.83; the consensus rating is “Strong buy”; expected EPS is $0.42 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is AVITA Medical stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 72% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does AVITA Medical pay a dividend?
Not currently.
Is AVITA Medical a good stock to buy?
We do not give buy or sell advice. AVITA Medical scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.